×

Control-to-range aggressiveness

  • US 10,332,633 B2
  • Filed: 06/01/2016
  • Issued: 06/25/2019
  • Est. Priority Date: 06/01/2016
  • Status: Active Grant
First Claim
Patent Images

1. A method of determining a basal rate adjustment of insulin in a continuous glucose monitoring system of a person with diabetes, the method comprising:

  • receiving, by at least one computing device, a signal representative of at least one glucose measurement;

    detecting, by the at least one computing device, a glucose state of the person based on the signal, the detected glucose state including a glucose level of the person and a rate of change of the glucose level;

    determining, by the at least one computing device, a current risk metric, the current risk metric indicating a risk of at least one of a hypoglycemic condition and a hyperglycemic condition of the person, wherein determining the current risk metric comprisesdetermining, by the at least one computing device, a return path based on a transition from the detected glucose state to a target glucose state, the return path comprising at least one intermediate glucose value associated with a return to the target glucose state;

    determining, by the at least one computing device, a cumulative hazard value of the return path, the cumulative hazard value including a sum of the hazard values of the at least one glucose value on the return path, each hazard value being indicative of a hazard associated with the corresponding intermediate glucose value; and

    determining, by the at least one computing device, a weighted average of cumulative hazard values of return paths generated from a glucose state distribution around the detected glucose state; and

    calculating, by the at least one computing device, an adjustment to a basal rate of a therapy delivery device based on the current risk metric and a control-to-range algorithm comprising at least one aggressiveness parameter, the aggressiveness parameter selected from;

    (a) scaling of a risk surface generated based on the risk metric with a scaling factor to adjust positive hazard values associated with hyperglycemia;

    (b) shifting of a risk surface generated based on the risk metric to account for insulin on board following a meal or correction bolus;

    (c) adjustment to a maximum allowed glucose acceleration, glucose acceleration representing the rate of change of glucose velocity and glucose velocity representing the rate of change of glucose values;

    (d) adjustment to a glucose state uncertainty representing the level of trust in the measured glucose state;

    or(e) combinations thereof.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×